Brad Canino
Stock Analyst at Guggenheim
(3.89)
# 531
Out of 5,161 analysts
23
Total ratings
56.52%
Success rate
10.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $72 → $68 | $13.95 | +387.63% | 2 | Feb 27, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $13.95 | +115.05% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $11.56 | +202.77% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.13 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $98.00 | +58.16% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.53 | +357.52% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $77.50 | +16.13% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $15.46 | +158.73% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $62.97 | +42.93% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $14.91 | +34.14% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $110.77 | -0.70% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $11.76 | +53.06% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $10.55 | +42.18% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.75 | +190.91% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.84 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $23.23 | +136.76% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $41.17 | -27.13% | 2 | Mar 31, 2021 |
Janux Therapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $72 → $68
Current: $13.95
Upside: +387.63%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $13.95
Upside: +115.05%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $11.56
Upside: +202.77%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.13
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $98.00
Upside: +58.16%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.53
Upside: +357.52%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $77.50
Upside: +16.13%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $15.46
Upside: +158.73%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $62.97
Upside: +42.93%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $14.91
Upside: +34.14%
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $110.77
Upside: -0.70%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $11.76
Upside: +53.06%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $10.55
Upside: +42.18%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.75
Upside: +190.91%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.84
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $23.23
Upside: +136.76%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $41.17
Upside: -27.13%